Companies Focus on ALS in Partnering AI, Drug Discovery Skills

Companies Focus on ALS in Partnering AI, Drug Discovery Skills

304818

Companies Focus on ALS in Partnering AI, Drug Discovery Skills

Bringing artificial intelligence (AI) to the development of small molecule therapies for amyotrophic lateral sclerosis (ALS) and other neurological diseases is the goal of a business partnership in Asia. The newly signed agreement is between Insilico Medicine, an AI-driven drug discovery company based in Hong Kong, and 4B Technologies of Suzhou, China, a biopharmaceutical specializing in nervous system disorders. A main aim of this collaboration is to use Insilico’s AI technologies to accelerate treatment discovery and development, while lowering…

You must be logged in to read/download the full post.